March is Multiple Myeloma Awareness Month: Learn About Recent Advances
There are several recent advances of note in the management of all stages of Multiple Myeloma.
Smoldering myeloma is considered to be a pre-cancerous condition, in which patients do not yet display any symptoms of multiple myeloma, but are at a high risk of progressing to multiple myeloma. The standard approach for smoldering myeloma has been observation. Now doctors have reported that a treatment combination consisting of Revlimid plus dexamethasone during smoldering myeloma appears to significantly improve long-term outcomes for patients. Patients with smoldering myeloma should schedule time with their physician to discuss their implications as a result of this new data.
A large, comparative, phase III HOVON clinical trial has again confirmed that upfront autologous stem cell transplantation (ASCT) should remain the treatment of choice in younger patients with newly diagnosed multiple myeloma and studies now demonstrate that the proteasome inhibitor Kyprolis appears superior to Velcade; Kyprolis treated patients lived twice as long without a worsening of disease compared with Velcade in a pivotal clinical trial.
New treatment options continue to evolve: CAR-T, or chimeric antigen receptor T-cells, is a new form of cancer immunotherapy in which a patient’s own T cells are removed and then engineered to identify and kill malignant multiple myeloma cells. The use of a patient’s own immune cells to fight cancer is proving to be a promising therapeutic approach and data on several other novel therapeutics were presented at ASH in December.
CancerConnect News coverage of advances in the management of Multiple Myeloma included the following key developments:
Advancements in Treatment-Multiple Myeloma Research News
- Early Treatment in Smoldering Myeloma Improves Long-Term Outcomes
- Scientific Highlights from American Society of Hematology Meeting
- Velcade® Revlimid®/Dexamethasone New Standard of Care for Newly Diagnosed Multiple Myeloma
- Darzalex® Approved for Additional Indications in Multiple Myeloma
- HOVON Trial: Autologous Stem Cell Transplant Remains Superior to Novel Agents for Treatment of Multiple Myeloma
- Aplidin® Improves Progression-Free Survival in Multiple Myeloma
- Farydak® Significantly Improves Outcomes for Heavily Pre-Treated Multiple Myeloma
- Yale Researchers Discover Underlying Cause of Myeloma
- Kyprolis® (Carfilzomib) Appears More Effective Than Velcade® (Bortezomib) In Patients With Relapsed Multiple Myeloma
- Combo Therapy of Kyprolis plus Dexamethasone Approved for Recurrent Multiple Myeloma
- Ask the Expert: Multiple Myeloma – Dr. Hofmeister Associate Professor in the Division of Hematology at OSU answers patient questions.
- Doctor, Patient, and Caregiver Communication: Now Available!
Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey?
- Sign up for monthly newsletters on multiple myeloma here.
- Get the facts about multiple myeloma here.
- Join ongoing discussions with other individuals affected by multiple myeloma in the CancerConnect private online multiple myeloma support group here.
- Follow CancerConnect on Facebook and Twitter.
Copyright © 2017 CancerConnect. All Rights Reserved.
More news and in-depth Multiple Myeloma information.